Global Point of Care Testing (POCT) Market, By Diagnostics Segment (Blood Glucose Testing, Cardiac Marker Testing, Lipid Panel/Cholesterol Testing, Coagulation Testing, Infectious Disease Testing, Urinalysis, Drug of Abuse Testing, Fecal Occult Blood Test

Global Point of Care Testing (POCT) Market, By Diagnostics Segment (Blood Glucose Testing, Cardiac Marker Testing, Lipid Panel/Cholesterol Testing, Coagulation Testing, Infectious Disease Testing, Urinalysis, Drug of Abuse Testing, Fecal Occult Blood Testing, Pregnancy & Fertility Testing, Tumor Marker Testing, Critical Care Testing, HbA1c Testing, Clinical Chemistry Testing, Bilirubin Testing, Hematology Testing), By Mode (Prescription-based Testing, OTC-based Testing), By Platform (Lateral Flow Assays, Immunoassays, Microfluidics, Dipsticks, Molecular Diagnostics, Others), By End User (Hospitals, Clinics, Laboratories, Assisted Living Healthcare Facilities, Home Care), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Trends, Recent Developments, Company Profiles - Forecast to 2031

The global point of care testing (POCT) market is predicted to reach US$ 79.30 Billion by 2031, from US$ 44.24 Billion in 2023. The demand for point of care testing is increasing across the globe, backed by increasing introduction of transportable, portable, and handheld instruments that has resulted in the migration of POC testing from the hospital environment to a range of medical environments including the workplace, home, disaster care and most recently, convenience clinics. The rising incidence of infectious diseases and chronic conditions such as cardiovascular diseases and diabetes have stimulated the demand for point of care testing services. Infectious diseases are one of the primary causes of mortality globally, as they claim approximately 17 million lives annually, making up around 30% of the 56 million deaths recorded worldwide. As per statistics of the International Diabetes Federation, in 2021, approximately 537 million adults (20-79 years) are living with diabetes globally, and it is estimated to reach 643 million by 2030 and 783 million by 2045. Hence, the growing incidence of infectious diseases and chronic conditions will drive the point of care testing market growth over the forecast period.

Besides, manufacturers in the POCT market are focusing on developing novel technologies for maximum testing within a minimum period. For instance, in February 2024, Abbott Laboratories secured regulatory approval from the FDA for its Binx Now COVID-19 & Flu A/B test. This point-of-care test has the capability to concurrently identify COVID-19, influenza A, and influenza B viruses, providing a more comprehensive diagnosis for respiratory infections at the point of care. Earlier, Abbott has introduced ID NOW, the world's quickest molecular POC test, which provides COVID-19 findings in 13 minutes and is usable in a variety of decentralized healthcare settings such as doctors' offices and urgent care clinics.

Recent Developments

In June 2024, Roche announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization for its cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, an automated multiplex real-time polymerase chain reaction (RT-PCR) assay on the cobas liat system.
In December 2023, QIAGEN AV introduced the QIAcube Connect, a novel automated sample-to-result PCR platform tailored for point-of-care settings. The primary goal of this platform is to furnish swift and precise molecular diagnostic outcomes in closer proximity to patients.
In June 2023, Sysmex Corporation launched a point-of-care testing system for rapid detection of antimicrobial susceptibility in Europe using a unique and proprietary microfluidic technology.

By Diagnostics Segment: Global Point of Care Testing Market & Forecast – Key Takeaways

Based on diagnostics segment, the blood glucose testing segment held majority share of the global point of care testing market. Increasing usage of home-based glucose monitoring systems is one of the key trends observed in the point of care diagnostics industry. In recent times, there has been increased use of blood glucose testing due to growing geriatric population, rising obese population, increasing lifestyle associated diseases and increasing prevalence of diabetes.
Cardiac marker segment is expected to grow at a significant rate over the forecast period. The growing prevalence of cardiovascular ailments, increasing purchasing power, rise in the geriatric population, associated with high susceptibility to chronic diseases related to cardiac disorders, and economical diagnosis of chronic diseases in rural areas is expected to drive the market for cardiac markers.
Infectious diseases are the primary cause of mortality as they claim approximately 17 million lives annually, making up around 30% of the 56 million deaths recorded worldwide. Infectious disease testing has shifted from centralized to decentralized POC testing, resulting in better patient care. For instance, Abbott has introduced ID NOW, the world's quickest molecular POC test, which provides COVID-19 findings in 13 minutes and is usable in a variety of decentralized healthcare settings.

By Mode: Global Point of Care Testing Market & Forecast – Key Takeaways

Based on mode, the point of care testing market is dominated by OTC-based testing segment, as these tests are cost-effective as well as easy operative in nature. OTC tests do not require dedicated space as clinical laboratory, and even their turn around time is quick.
The Prescription based testing segment is expected to grow at the highest rate over the forecast period.

By Platform: Global Point of Care Testing Market & Forecast – Key Takeaways

By platform, the Lateral Flow Assays (LFA) segment accounted for largest revenue share in 2023. Lateral flow assays are simple devices used to detect the presence or absence of target analytes in samples. In the past few years, the POC diagnostics market for LFA has grown significantly due to the increasing adoption of LFA testing products in home care settings.
The point of care testing market for immunoassays technology is expected to witness significant growth over the forecast timeframe. Rapid immunoassays improve quality of care through its performance at point of care facilities, such as student health clinics, labor and delivery suites and emergency rooms. The cost-effectiveness offered by these immunoassays will influence segment growth over the forecast period.
Molecular diagnostics segment is likely to witness the highest growth over the forecast period, driven by increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics, increasing R&D funding, growing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests.
Microfluidic based point-of-care testing provides prompt results and also improves disease detection and diagnosis with the help of small sample volumes.

By End Users: Global Point of Care Testing Market & Forecast – Key Takeaways

Based on end users, the point of care testing market is segmented into Hospitals, Clinics, Laboratories, Home Care and Assisted Living Healthcare Facilities.
Hospitals held majority of the point of care testing market, followed by Clinics. Increase in prevalence of chronic conditions such as cancer and cardiovascular diseases that require proper monitoring and prefer minimally invasive procedures are carried out in hospitals and clinics. The use of point of care testing devices in clinics is expanding at a significant pace. A significant number of Clinical Laboratory Improvement Amendments (CLIA)-waived tests are implemented within clinics for diagnosis of a diverse range of disorders.
The home care segment is expected to grow at the highest rate over the forecast period driven by increasing preference for home and remote monitoring and rising demand for rapid tests among home care users. Availability of cost-effective and user-friendly alternatives for disease management will stimulate the segmental growth over the forecast timeframe.

By Region: Global Point of Care Testing Market & Forecast – Key Takeaways

North America captured highest share of the global point of care testing market in 2023. This can be attributed to rising prevalence of chronic disorders and infectious diseases, which need portable and rapid diagnosis, increasing number of product approvals, and rising government initiatives to support the adoption of POCT in this region.
Europe held second highest share of the global point of care testing market. The growth would be supported by the launch of new products, innovative technological revolution, rising prevalence of chronic disorders and infectious diseases, and increase in reliability on POCT products by home patients & institutional buyers.
Asia-Pacific point of care testing market is expected to grow at a lucrative rate over the forecast period, driven by four major factors namely growing geriatric population base in countries such as Japan and China, rising prevalence of target diseases, increasing demand for home healthcare and the introduction of new products enabled with advanced technologies.

iGATE RESEARCH report titled “Global Point of Care Testing (POCT) Market, By Diagnostics Segment (Blood Glucose Testing, Cardiac Marker Testing, Lipid Panel/Cholesterol Testing, Coagulation Testing, Infectious Disease Testing, Urinalysis, Drug of Abuse Testing, Fecal Occult Blood Testing, Pregnancy & Fertility Testing, Tumor Marker Testing, Critical Care Testing, HbA1c Testing, Clinical Chemistry Testing, Bilirubin Testing, Hematology Testing), By Mode (Prescription-based Testing, OTC-based Testing), By Platform (Lateral Flow Assays, Immunoassays, Microfluidics, Dipsticks, Molecular Diagnostics, Others), By End User (Hospitals, Clinics, Laboratories, Assisted Living Healthcare Facilities, Home Care), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Trends, Recent Developments, Company Profiles - Forecast to 2031” provides a comprehensive analysis of the Global Point of Care Testing Market.


This 308 Page report with 73 Figures and 12 Tables has been analyzed from 10 View Points:

1) Global - Point of Care Testing Market & Forecast (2015 - 2031)
2) Global - Point of Care Testing Market Share and Forecast (2015 - 2031)
3) By Diagnostics Segment - Global Point of Care Testing Market & Forecast (2015 - 2031)
4) By Mode - Global Point of Care Testing Market & Forecast (2015 - 2031)
5) By Platform - Global Point of Care Testing Market & Forecast (2015 - 2031)
6) By End Users - Global Point of Care Testing Market & Forecast (2015 - 2031)
7) By Region - Global Point of Care Testing Market & Forecast (2015 - 2031)
8) Global Point of Care Testing Market - Recent Developments

9) Global Point of Care Testing Market - 104 Company Profiles
10) Global Point of Care Testing Market - Growth Drivers & Challenges

By Diagnostics Segment - Global Point of Care Testing Market & Forecast

1. Blood Glucose Testing
2. Cardiac Marker Testing
3. Lipid Panel/Cholesterol Testing
4. Coagulation Testing
5. Infectious Disease Testing
6. Urinalysis Testing
7. Drug of Abuse Testing
8. Fecal Occult Blood Testing
9. Pregnancy & Fertility Testing
10. Tumor Marker Testing
11. Critical Care Testing
12. HbA1c Testing
13. Clinical Chemistry Testing
14. Bilirubin Testing
15. Hematology Testing

By Mode - Global Point of Care Testing Market & Forecast

Prescription-based Testing
TC-based Testing

By Platform - Global Point of Care Testing Market & Forecast

Lateral Flow Assays
Immunoassays
Microfluidics
Dipsticks
Molecular Diagnostics
Others

By End Users - Global Point of Care Testing Market & Forecast

1. Hospitals
2. Clinics
3. Laboratories
4. Assisted Living Healthcare Facilities
5. Home Care

By Region - Global Point of Care Testing Market & Forecast

1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East & Africa

Global Point of Care Testing Market - 104 Company Profiles

1. Abbott Laboratories
2. Siemens Healthineers
3. Roche Diagnostics
4. Quest Diagnostics
5. Becton, Dickinson and Company
6. ACON Laboratories
7. Abaxis, Inc
8. Abingdon Health, Ltd
9. Access Bio, Inc.
10. AccuBioTech Co, Ltd.
11. Akers Biosciences, Inc.
12. Alfa Scientific Designs, Inc
13. American Bio Medica Corporation
14. AmniSure International
15. Aquila Diagnostic Systems, Inc
16. ARKRAY Inc
17. Artron Laboratories Inc.
18. Ascensia Diabetes Care Holdings AG
19. Immune IQ (Formerly Ativa)
20. Atlas Link Biotech Co., Ltd
21. Audit Diagnostics
22. Augurix Diagnostics
23. Autobio Diagnostics Co., Ltd
24. Axxin
25. Beckman Coulter, Inc
26. Bhat Bio-Tech India Private Ltd.
27. bioLytical Laboratories
28. BioMedomics, Inc
29. Biomerica, Inc.
30. bioMerieux SA
31. Biophor Diagnostics, Inc
32. Bio-Rad Laboratories Inc.
33. Bioscan Screening Systems, Inc.
34. Biosensia Ltd.
35. BTNX Inc.
36. Boditech Med Inc
37. Xiamen Boson Biotech Co. Ltd
38. Calypte Biomedical Corporation
39. Cepheid, Inc
40. Chembio Diagnostic Systems, Inc. (Acquired by Biosynex SA)
41. Clarity Diagnostics, LLC
42. Confirm Biosciences
43. CTK Biotech, Inc.
44. Danaher Corporation
45. Dexcom, Inc
46. DIALAB GmbH
47. DiaSys Diagnostic Systems GmbH
48. Diazyme Laboratories, Inc.
49. DNA Electronics Ltd. (DNAe)
50. EKF Diagnostics Holdings plc
51. ELITechGroup, Inc.
52. Eurolyser Diagnostica GmbH
53. Exact Sciences Corporation
54. Exalenz Bioscience Ltd. (Acquired by Meridian Bioscience, Inc.)
55. Genedrive plc
56. GeTein BioMedical, Inc.
57. Helena Laboratories
58. Hemosure, Inc.
59. Immunostics, Inc.
60. Instrumentation Laboratory
61. JAL Innovation PTE LTD
62. Jant Pharmacal Corporation
63. LamdaGen Corporation
64. LifeScan, Inc
65. LifeSign, LLC
66. MBio Diagnostics, Inc (Now LightDeck Diagnostics)
67. Medix Biochemica
68. Medtronic, Inc
69. A. Menarini Diagnostics S.R.L.
70. Meridian Bioscience, Inc
71. Nano-Ditech Corporation
72. Noble Medical, Inc
73. Nova Biomedical, Corp.
74. Oasis Diagnostics Corporation
75. OPTI Medical Systems, Inc
76. OPKO Health, Inc
77. OraSure Technologies, Inc
78. Polymed Therapeutics Inc.
79. Preventis GmbH
80. Princeton Biomeditech Corporation
81. QuantuMDx Group Limited
82. Radiometer Medical A/S
83. Response Biomedical Corp
84. Reszon Diagnostics International Sdn. Bhd.
85. Samsung Healthcare
86. Savyon Diagnostics
87. Sekisui Diagnostics LLC
88. Siloam Biosciences, Inc
89. Sysmex Corporation
90. TECHLAB, Inc.
91. Teco Diagnostics
92. Trinity Biotech PLC
93. Trividia Health
94. Tulip Diagnostics Ltd
95. Veredus Laboratories PTE Ltd
96. Vircell
97. WAMA Diagnostica
98. Wave 80 Biosciences
99. Werfen
100. Quidel Corporation
101. Thermo Fisher Scientific
102. Mesa Biotech Inc
103. GeneSTAT Molecular Diagnostics, LLC
104. Biocartis Group NV

Data Source

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies:

Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies:

Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.